Independent Validation

A study by Dr Zang & Professor Ware of the Biostatistics Unit at Griffith University of Queensland, Australia has independently validated the CardiAction cardiovascular screening model, confirming its strong correlation with actual central systolic blood pressure (CSBP) measurements obtained through Pulse Wave Analysis (PWA).

Scientific Research Overview

The study analysed 935 data points from multiple healthcare settings. assessing how well CardiAction's predictive model (CSBP_Proxy) aligns with actual clinical measurements (CSBP Actual). Key findings include:

Strong correlation (R=0.785, P<0.001) between CardiAction's CSBP Proxy and clinically measured CSBP, demonstrating high predictive accuracy.
Average margin of error at just 8.8%, reinforcing CardiAction's reliability in assessing cardiovascular risk.
Improved accuracy for individuals with lower CSBP values (<150 mmHg), where the model's predictive error drops to 8.0%
Correlation with existing Australian & New Zealand cardiovascular risk scores, supporting its validity as a risk assessment tool.

Conclusion

These results confirm CardiAction's capability as a non-invasive cardiovascular screening tool, providing reliable insights without requiring a blood test. The Griffith University findings reinforce CardiAction as an evidence-based solution for proactive heart health screening.

Strong Predictive Accuracy

R=0.785, P<0.0010%

CardiAction's central systolic blood pressure (CSBP Proxy) strongly correlates with actual clinical measurements (CSBP Actual)

Enhanced Accuracy for Lower Blood Pressure Values

RMSE 9.69, 8.0%

CardiAction provides an accurate estimate of central systolic blood pressure with a low average error margin.

Low Margin of Error

RMSE 10.97, 8.8% of Mean CSBP

CardiAction provides an accurate estimate of central systolic blood pressure with a low average error margin